Approval · Notice of Compliance 26480 · 2021
MOVIPREP: Notice of Compliance 26480
Issued August 20, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26480
- Date
- August 20, 2021
- Company
- Aralez Pharmaceuticals Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Response to advisement letter
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MOVIPREP | Not yet assigned | — |
Medicinal ingredients
- ASCORBIC ACID 4.7 G per SACHET
- POLYETHYLENE GLYCOL 3350 100 G per SACHET
- POTASSIUM CHLORIDE 1.015 G per SACHET
- SODIUM ASCORBATE 5.9 G per SACHET
- SODIUM CHLORIDE 2.691 G per SACHET
- SODIUM SULFATE ANHYDROUS 7.5 G per SACHET